We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+15.44%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$546M
AUM Growth
+$63.4M
(+13%)
Cap. Flow
+$26M
Cap. Flow
% of AUM
4.75%
Top 10 Holdings %
Top 10 Hldgs %
90.77%
Holding
17
New
4
Increased
1
Reduced
–
Closed
1
Avg Time Held
3.8
quarters
Top 10 Avg Time Held
4.7
quarters
Top 20 Avg Time Held
3.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gritstone bio, Inc. Common Stock
GRTS
|
+$29.4M |
| 2 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
+$14.2M |
| 3 |
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
|
+$12.1M |
| 4 |
Krystal Biotech
KRYS
|
+$10.5M |
| 5 |
Synlogic
SYBX
|
+$464K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$40.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$1.36B
| $231M | 42.32% |
2,316,447
| – | – |
2017 Q1
6 quarters
|
|
|
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
| $92.4M | 16.92% |
3,190,079
| – | – |
2018 Q2
1 quarter
|
|
|
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
| $35.8M | 6.55% |
3,330,373
| – | – |
2017 Q4
3 quarters
|
|
|
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $29.4M | 5.38% |
+2,061,762
| New | +$29.4M |
2018 Q3
0 quarters
|
|
5
Collegium Pharmaceutical
COLL
$701M
| $27.8M | 5.09% |
1,887,332
| – | – |
2015 Q4
11 quarters
|
|
6
Iovance Biotherapeutics
IOVA
$6.57B
| $24.6M | 4.51% |
2,188,331
| – | – |
2016 Q2
9 quarters
|
|
|
ETTX
7
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $14.7M | 2.69% |
+1,349,953
| New | +$14.2M |
2018 Q3
0 quarters
|
|
8
DELISTED
Alpine Immune Sciences Inc
ALPN
| $13.9M | 2.55% |
2,199,011
| – | – |
2017 Q3
4 quarters
|
|
|
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $13.8M | 2.53% |
202,803
| – | – |
2015 Q4
11 quarters
|
|
|
10
DELISTED
Synlogic
SYBX
| $12.3M | 2.25% |
57,694
+2,929
| +5% | +$464K |
2018 Q1
2 quarters
|
|
|
NBRV
11
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $11.5M | 2.1% |
+17,026
| New | +$12.1M |
2018 Q3
0 quarters
|
|
|
12
Krystal Biotech
KRYS
$9.51B
| $11M | 2.01% |
+625,000
| New | +$10.5M |
2018 Q3
0 quarters
|
|
13
DELISTED
Iterum Therapeutics
ITRM
| $10.3M | 1.89% |
102,554
| – | – |
2018 Q2
1 quarter
|
|
|
BLCM
14
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $6.48M | 1.19% |
105,144
| – | – |
2018 Q2
1 quarter
|
|
15
DELISTED
Cidara Therapeutics
CDTX
| $5.77M | 1.06% |
65,613
| – | – |
2015 Q4
11 quarters
|
|
16
DELISTED
Kezar Life Sciences
KZR
| $5.35M | 0.98% |
25,000
| – | – |
2018 Q2
1 quarter
|
|
|
17
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-2,600,014
| Closed | -$40.6M | – |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q3 2018 Portfolio in Review
As of Q3 2018, Frazier Management held 17 positions worth $546M, up 13% from $483M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Frazier Management deployed $26M of net new capital in Q3 2018, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Gritstone bio, Inc. Common Stock: 2,061,762 shares worth $29.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the most notable exit was Amicus Therapeutics, an estimated $40.6M sold.
- Frazier Management's largest Q3 2018 buy was Gritstone bio, Inc. Common Stock: 2,061,762 shares worth $29.4M.
- Frazier Management added most to Synlogic in Q3 2018, an estimated $464K increase.
- Frazier Management fully exited Amicus Therapeutics in Q3 2018, selling an estimated $40.6M.
- Frazier Management's ten largest holdings make up 91% of its $546M portfolio in Q3 2018.
- Frazier Management opened 4 new positions and closed 1 in Q3 2018.
- Frazier Management's portfolio value rose 13% quarter-over-quarter to $546M.
Based on Frazier Management's 13F filing for Q3 2018, filed 14 Nov 2018.